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A systematic review and meta-analysis of
premature mortality in bipolar aﬀective
disorder
Hayes JF, Miles J, Walters K, King M, Osborn DPJ. A systematic
review and meta-analysis of premature mortality in bipolar aﬀective
disorder.
Objective: To review and complete meta-analysis of studies estimating
standardised mortality ratios (SMRs) in bipolar aﬀective disorder
(BPAD) for all-cause and cause-speciﬁc mortalities.
Method: Cause-speciﬁc mortality was grouped into natural and
unnatural causes. These subgroups were further divided into
circulatory, respiratory, neoplastic and infectious causes, and suicide
and other violent deaths. Summary SMRs were calculated using
random-eﬀects meta-analysis. Heterogeneity was examined via
subgroup analysis and meta-regression.
Results: Systematic searching found 31 studies meeting inclusion
criteria. Summary SMR for all-cause mortality = 2.05 (95% CI 1.89–
2.23), but heterogeneity was high (I2 = 96.2%). This heterogeneity
could not be accounted for by date of publication, cohort size, mid-
decade of data collection, population type or geographical region.
Unnatural death summary SMR = 7.42 (95% CI 6.43–8.55) and
natural death = 1.64 (95% CI 1.47–1.83). Speciﬁcally, suicide
SMR = 14.44 (95% CI 12.43–16.78), other violent death SMR = 3.68
(95% CI 2.77–4.90), deaths from circulatory disease = 1.73 (95% CI
1.54–1.94), respiratory disease = 2.92 (95% CI 2.00–4.23),
infection = 2.25 (95% CI 1.70–3.00) and neoplasm = 1.14 (95% CI
1.10–1.21).
Conclusion: Despite considerable heterogeneity, all summary SMR
estimates and a large majority of individual studies showed elevated
mortality in BPAD compared to the general population. This was true
for all causes of mortality studied.
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Summations
• All-cause and cause-speciﬁc mortalities are elevated in individuals with bipolar aﬀective disorder rela-
tive to the general population.
• As well as dramatic elevations in suicide risk, there is a mortality gap from all medical illnesses exam-
ined.
Considerations
• Heterogeneity was high in all-cause and in many cause-speciﬁc standardised mortality ratio esti-
mates.
• Heterogeneity could not be accounted for by any of the study-level variables available.
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Introduction
An increasing body of research has shown that
bipolar aﬀective disorder (BPAD) is associated
with premature mortality. Where previously it
was believed this was mostly attributable to
unnatural causes such as suicide, homicide and
accidents, it has also been shown that patients
with BPAD are also at risk of premature death
from a range of medical illnesses (1). In 1998,
Harris and Barraclough (2) reviewed mortality in
all mental disorders. Six studies contributed to
their meta-analysis of mortality in BPAD. A
more recent review published in 2009 included 13
studies (1). However, this review only searched
one database and included patients without a
clear diagnosis of BPAD (such as mixed unipolar/
bipolar groups). Since these publications, a num-
ber of large database studies have derived stan-
dardised mortality ratio (SMR) estimates. The
SMR is an indirect method of standardisation
calculated by the ratio of observed deaths in the
study group to expected deaths in the general
population.
The issue of premature mortality, beyond sui-
cide, has been understudied in BPAD compared
with other disorders, such as schizophrenia and
unipolar depression (3), and there is a lack of clear
evidence in this area. There is likely to be
considerable heterogeneity amongst SMR
estimates. Overreliance on either inpatient data or
community-based samples is an important limita-
tion. The sole use of inpatient data may potentially
result in bias and poor generalisability by including
only more severe cases, whereas community-based
samples are often limited by insuﬃcient sample
sizes. Heterogeneity may also be introduced by
period eﬀects and by comparing treated and
untreated groups.
Aims of the study
To estimate all-cause and cause-speciﬁc mortalities
in bipolar aﬀective disorder via a systematic review
and meta-analysis of cohort studies.
Material and methods
Existing studies of SMR in BPAD were systemat-
ically reviewed to examine the association
between BPAD and all-cause and cause-speciﬁc
mortality. Cause-speciﬁc mortality was grouped
into natural and unnatural causes. These sub-
groups were further divided into suicide and
other violent deaths, and deaths from circulatory,
respiratory, neoplastic and infectious causes.
Heterogeneity was assessed by geographical
region, population type, cohort size, mid-decade
of cohort data collection and decade of publica-
tion. We closely followed the guidance provided
by the PRISMA statement and MOOSE pro-
posal for reporting (4, 5).
Identification of studies
To identify all studies examining mortality in
BPAD, the Medical Subject Heading (MeSH)
terms and keywords for BPAD and mortality
were searched in PsycINFO, MEDLINE and
EMBASE. MeSH terms were as follows: bipolar
disorder, mortality, life expectancy, death, death
and dying. Keywords searched were as follows:
bipolar illness, manic depression, bipolar disorder,
bipolar aﬀective disorder, life expectancy, mortal-
ity and death (full search terms are available from
the corresponding author on request). All data-
bases were searched from their inception until 30
July 2014. JFH and JM performed the searches
individually and then compared results. The
abstracts of potentially relevant articles were
reviewed by both JFH and JM. Additional arti-
cles and conference papers including primary
data were identiﬁed from citations in relevant
studies and reviews, the Cochrane database of
systematic reviews and Google Scholar. Emails
were then sent to senior authors of articles that
met inclusion criteria to attempt to identify all
missing studies. One extra-published study was
identiﬁed by this method, and no further unpub-
lished data were made available (Fig. 1).
Inclusion and exclusion criteria
Included studies met all of the following a priori
deﬁned criteria:
i) Published between 1 January 1960 and 30 July
2014.
ii) Reported deaths of people diagnosed with
BPAD; studies were included if BPAD was
diagnosed by any criteria.
iii) Individuals included in the study were 16 years
or older.
iv) Primary data on all-cause mortality or cause-
speciﬁc mortality were included; speciﬁc sub-
categories of mortality were as follows: natural
deaths, unnatural deaths, suicide, other violent
deaths, infection, neoplasm, respiratory and
circulatory system disease.
v) Reported data on observed and expected
deaths, or SMR allowing the number of
observed and expected deaths to be calculated.
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Studies were excluded if they:
i) Involved cohorts that could not be deﬁned as
having BPAD (i.e. studies which grouped
together aﬀective disorders).
ii) Included a cohort of <50 patients (to avoid
including cohorts in which there were no
observed deaths).
iii) Were not standardised by age.
iv) Reported mortality in a particular subgroup of
the population with BPAD (i.e. prison popula-
tion).
v) Reported duplicate data (or data sets from
overlapping time periods at the same site).
Study-level information was ﬁltered to identify
data from multiple studies that overlapped in place
and time. The most informative paper was then
used as the representative mortality estimate for
inclusion in the meta-analysis (i.e. larger samples
and longer time periods were preferred).
Data extraction
Once a study was included, data were extracted
and entered into a database that included study-
level variables [authors, country, year of publica-
tion, years of data collection, length follow-up,
which covariates the mortality was standardised
by, the site of collection (i.e. multiple site or popu-
lation level), the population type (i.e. inpatient or
community)] and estimate-level variables (number
of men and women in the cohort, deaths from all
causes and speciﬁc causes for both men and
women, and population-level estimates of expected
deaths).
JFH and JM individually extracted data used in
the analysis using a standardised form. If disagree-
ments arose, these were resolved by consensus.
When required, we contacted the original authors
for clariﬁcation of issues.
Statistical methods
The SMR gives the ratio of death in BPAD com-
pared to the general population. For each cause of
death, SMRs and their 95% conﬁdence intervals
were extracted from each publication or calculated
(observed deaths/expected deaths).
The statistical signiﬁcance of the SMR is based
on the Poisson distribution (two-tailed) using 95%
conﬁdence intervals. The SMR is signiﬁcantly
Fig. 1. Flow diagram of the published
articles evaluated for inclusion in this
meta-analysis.
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raised when the lower conﬁdence interval is >1.00.
For each study, 95% CIs were calculated using
the Rothman–Greenland method (6). Pooled
SMRs with 95% CI for all-cause and cause-spe-
ciﬁc mortalities were calculated using the DerSi-
monian and Laird method, a random-eﬀects
model that incorporates both between-study and
within-study variation (7). Using this method
assumes that signiﬁcant heterogeneity exists
between studies.
Statistical heterogeneity was assessed in a num-
ber of ways. First, the I2 index and chi-square test
were used to investigate diﬀerences amongst
studies with respect to SMRs. Additionally, meta-
regression analysis was performed for heterogene-
ity of the all-cause SMR because of decade of
publication, cohort size, geographical region,
mid-decade of cohort data collection and popula-
tion type (i.e. inpatient or community). Subgroup
analyses were performed to assess potential
sources of heterogeneity separately as a result of
the following available patient-level and study-
level factors: geographical region of study, patient
population type and decade of the middle year of
patient observation. These were considered to be
the key sources of potential bias in the included
studies. Funnel plots and Egger’s regression were
used to assess for publication and small-study bias
in groups containing 10 or more studies (8).
All analysis was completed using metan and
associated commands in STATA 13 (9).
Results
The inclusion criteria were met by 31 published
studies including unique data sets (10–40) (Fig. 1,
Table 1). Of these, 64% were inpatient cohorts. A
large number (45%) of studies came from Scandi-
navian countries (Norway, Sweden, Denmark and
Finland). Overall, there were 305 859 people with
a diagnosis of BPAD (not including individuals in
studies 24 and 31, which only presented person-
years at risk). Data collection ranged from 1935 to
2010.
The reported SMRs for all-cause mortality in
patients with BPAD ranged from 1.24 (95% CI
0.83–1.17) to 4.65 (95% CI 1.27–11.91). Within the
26 individual studies assessing all-cause mortality,
all SMR point estimates were elevated, but four of
26 had conﬁdence intervals that overlapped one
(13, 21, 26, 29), and these were all relatively small
studies (N < 440). The all-cause summary SMR
for bipolar disorder was 2.05 (95% CI 1.89–2.23).
There was signiﬁcant heterogeneity between these
studies (I2 = 96.2%, 95% CI 95.6–96.7, P < 0.001)
(Fig. 2).
Sex-speciﬁc all-cause mortality showed similarly
elevated summary estimates, but again the studies
were highly heterogeneous (Table 2). This was also
true for mortality grouped as natural and unnatu-
ral. Studies had heterogeneous SMR estimates for
suicide, other violent deaths and circulatory dis-
ease mortality. Estimates for SMRs for infectious
and neoplastic deaths were more homogenous.
Summary estimates suggested increased rates of
death from all causes in people with bipolar disor-
der (Table 2).
In univariable meta-regression, all-cause mor-
tality was not signiﬁcantly associated with decade
of publication (P = 0.63), cohort size (P = 0.75),
geographical region (P = 0.55), mid-decade of
cohort data collection (P = 0.89) or population
type (P = 0.65). After accounting for all of these
possible explanatory variables in multivariable
meta-regression, residual variation due to hetero-
geneity amongst all-cause mortality SMRs
remained (I2 = 88.3%, 95% CI 84.6–90.7, P <
0.001).
Subgroup analyses were performed stratiﬁed by
geographical region, population type and mid-dec-
ade of study (Table 3). Stratifying by these covari-
ates had little eﬀect on heterogeneity in summary
estimates for all-cause, natural and unnatural
death SMRs, which remained high.
For all-cause mortality SMR, Eggers test did
not suggest signiﬁcant publication bias (P = 0.63).
The same was true for SMR of unnatural deaths
(P = 0.55) and suicide (P = 0.40). However, given
the high heterogeneity publication bias cannot be
ruled out with certainty in these groups. It is even
more likely to be present in studies of natural
deaths (P = 0.05) and circulatory disease
(P = 0.17).
Discussion
This review of mortality in patients with BPAD
highlights the increased risk of death from all
causes. Summary SMR estimates from random-
eﬀects meta-analysis showed that all-cause mortal-
ity in BPAD is double that expected in the general
population. Natural deaths are over 1.5 times
greater in BPAD than the general population;
these natural deaths are made up of an almost dou-
ble risk of deaths from circulatory illnesses (heart
attacks, strokes, etc.) and three times risk of deaths
from respiratory illness (COPD, asthma, etc.).
Unnatural deaths are around seven times more
common, with increased risk of suicide of around
14 times and other violent deaths (accidents, homi-
cide, etc.) almost four times as likely. Deaths by
all causes were similarly elevated in both men
420
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and women. Of particular concern is the lack of
association between mid-decade of cohort follow-
up and SMR: having BPAD in the 2000s has the
same mortality risk compared to the general popu-
lation as it did in the 1950s. With the increased use
of second-generation antipsychotics in these
cohorts (41, 42) and associated elevated risk of car-
diovascular disease, the failure of smoking cessa-
tion policy to address the needs of the severely
mentally ill, relative to the general population (43,
44) and the continued lack of equality in access to
health care for people with BPAD (43), this gap in
deaths from medical illness may to widen unless it
is directly addressed. In terms of modifying the
increased rate of unnatural deaths, particular
attention needs to be paid to comorbid substance
misuse, risk of coercion, exploitation, receipt and
perpetration of violence, and suicidal ideation (44–
46).
Heterogeneity across studies was high (less so
for deaths from cancer and infection). Heterogene-
ity in all-cause mortality, and natural and unnatu-
ral death SMRs could not be accounted for by
year of publication, study size, mid-point of data
collection, geographical region or population type.
Whilst it is possible that some of these factors were
imperfectly adjusted for in the analysis (for exam-
ple some cohorts spanned many decades), the
results suggest that there are unidentiﬁed factors
that led to diﬀerences in outcomes for diﬀerent
cohorts of patients with BPAD. It has been shown
that patients with BPAD in the United States have
worse physical health and greater comorbidity
than those in Germany and the Netherlands (47);
however, it may be the case that there are even
more localised diﬀerences in BPAD outcomes.
This meta-analysis suggests that within the US or
Europe, mortality estimates for BPAD are not
Fig. 2. Standardised mortality ratio (SMR) of all-cause mortality. CI, conﬁdence interval; % weights are from random-eﬀects
analysis.
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homogenous. Adjusting for cohort size did little to
reduce the heterogeneity, despite the increased
accuracy in SMR estimates larger studies should
provide. Stratifying by decade of data collection
did not aﬀect heterogeneity, suggesting that the
diﬀerences are not down to improvements in treat-
ment over time. Studies of inpatient populations
and community cohorts were also heterogeneous,
suggesting these diﬀerences are not down to
engagement with services or severity of illness.
There are several limitations of studies included
in this review. SMRs were often only age and sex
adjusted; therefore, other characteristics of the
study populations, such as illness duration and life-
style factors, may have contributed to the signiﬁ-
cant heterogeneity. For example, it was not
possible to assess whether current or former smok-
ing contributed to excess respiratory mortality.
Disease severity was not assessed in all of the
included studies, and therefore, it is not possible to
assess heterogeneity in the overall mortality by
severity. It has been recognised that patients with
bipolar disorder accumulate numerous medical
risk factors including smoking, use of alcohol and
other illicit drugs, prescribed medication and co-
morbid anxiety and eating disorders that lead to
earlier disease onset, poor engagement with health
care and poor long-term outcomes (48). These risk
factors may be assigned diﬀerentially, both geo-
Table 2. Summary SMRs for all-cause and cause specific mortalities
No. of
studies
Number of
individuals*
Summary
SMR (95°% CI) I2 (95% CI)
Het
P
All-cause 26 220 134 2.05 (1.89–2.23) 96.2 (95.6–96.7) <0.001
Men 15 34 636 2.17 (2.01–2.34) 83.6 (74.8–88.3) <0.001
Women 15 46 075 2.11 (1.93–2.31) 84.4 (83.4–91.39) <0.001
Natural 12 159 495 1.64 (1.47–1.83) 98.0 (98.0–98.5) <0.001
Men 9 34 220 1.72 (1.54–1.93) 94.5 (92.5–95.8) <0.001
Women 9 45 598 1.74 (1.51–1.99) 97.6 (97.1–98.0) <0.001
Unnatural 12 159 434 7.42 (6.43–8.55) 95.6 (93.9–96.2) <0.001
Men 9 34 142 7.89 (7.05–8.81) 82.4 (68.1–88.6) <0.001
Women 9 45 515 9.23 (7.14–11.94) 96.6 (95.6–97.2) <0.001
Suicide 15 46 756 14.44 (12.43–16.78) 87.0 (80.4–90.7) <0.001
Men 9 12 325 13.31 (10.62–16.69) 87.8 (78.7–91.9) <0.001
Women 9 16 698 15.74 (12.84–19.31) 81.7 (63.4–88.7) <0.001
Other violent 5 22 641 3.68 (2.77–4.90) 89.5 (77.2–93.8) <0.001
Men 4 9463 3.06 (2.19–4.03) 86.2 (57.6–92.8) <0.001
Women 4 12 958 5.53 (1.60–19.14) 99.0 (98.7–99.19) <0.001
Circulatory 14 153 948 1.73 (1.54–1.94) 95.2 (93.9–96.1) <0.001
Men 9 34 041 1.81 (1.61–2.05) 90.3 (85.1–93.1) <0.001
Women 9 45 396 1.72 (1.46–2.03) 96.0 (94.8–96.82) <0.001
Respiratory 5 22 609 2.92 (2.00–4.23) 94.14 (89.8–96.1) <0.001
Men 4 9278 2.73 (1.76–4.24) 90.2 (75.9–94.5) <0.001
Women 4 12 726 2.72 (1.78–4.20) 91.3 (80.0–94.99) <0.001
Infection 5 22 895 2.25 (1.70–3.00) 45.4 (0.0–78.5) 0.12
Men 4 9323 2.76 (1.94–3.92) 43.1 (0.0–80.0) 0.15
Women 4 12 781 1.77 (1.30–2.40) 20.9 (0.0–74.1) 0.29
Neoplasm 10 27 693 1.14 (1.10–1.21) 20.7 (0.0–61.9) 0.25
Men 7 9729 1.11 (1.05–1.17) 0.0 (0.0–58.5) 0.47
Women 7 13 214 1.19 (1.05–1.37) 56.3 (0.0–79.3) 0.03
SMR, standardised mortality ratio; CI, confidence interval; I2, index of heterogeneity;
Het P, from x2 test.
*Not including individuals in studies 24 and 31.
Table 3. Summary SMRs by subgroup for all-cause mortality, and natural and
unnatural death
No. of
studies
Summary
SMR (95% CI) I2 (95% CI) Het P
All-cause
Geographical region
Scandinavia 10 2.20 (2.01–2.41) 96.5 (95.2–97.5) <0.001
North America 3 1.77 (1.24–2.53) 81.4 (42.7–94.0) 0.005
UK 8 2.06 (1.74–2.34) 91.7 (86.0–95.1) <0.001
Other European 4 1.67 (1.18–2.38) 51.7 (0.0–84.1) 0.1
Japan 1 1.93 (1.44–2.52) – –
Population type
Inpatient 17 2.05 (1.86–2.25) 97.3 (96.9–97.7) <0.001
Inpatient and
community
6 2.21 (1.79–2.73) 80.6 (49.1–89.4) <0.001
Community 3 1.85 (1.16–2.94) 77.6 (0.0–91.1) 0.01
Mid-point of study
1950s 2 1.86 (0.88–3.94 90.9* 0.001
1960s 3 1.85 (1.58–2.17) 0.0 (0.0–72.9) 0.7
1970s 6 1.93 (1.67–2.24) 82.5 (60.8–89.8) <0.001
1980s 6 2.30 (1.84–2.87) 84.1 (62.3–90.9) <0.001
1990s 3 2.12 (1.42–3.14) 99.3 (99.0–99.4) <0.001
2000s 5 2.13 (1.90–2.39) 95.7 (93.9–96.8) <0.001
Natural
Geographical region
Scandinavia 6 1.79 (1.56–2.05) 98.8 (98.6–99.0) <0.001
North America 2 1.34 (0.90–2.00) 64.9* 0.09
UK 3 1.42 (0.95–2.12) 98.7 (98.1–99.0) <0.001
Other European 1 1.40 (1.17–1.66) – –
Population type
Inpatient 10 1.67 (1.48–1.88) 96.1 (95.0–96.9) <0.001
Inpatient and
community
1 1.79 (1.68–1.91) – –
Community 1 1.03 (0.71–1.44) – –
Mid-point of study
1950s 1 1.10 (0.79–1.49) – –
1960s 0 – – –
1970s 3 1.36 (1.23–1.51) 0.0 (0.0–72.9) 0.43
1980s 3 1.51 (1.14–2.00) 99.1 (98.8–99.3) <0.001
1990s 2 2.06 (2.00–2.12) 0.0* 0.62
2000s 3 1.75 (1.50–2.03) 97.1 (95.8–97.9) <0.001
Unnatural
Geographical region
Scandinavia 6 8.15 (7.20–9.24) 94.0 <0.001
North America 2 3.12 (1.97–4.96) 0* 0.75
UK 2 7.90 (3.16–19.73) 99.2* <0.001
Other European 2 5.60 (2.42–12.95) 31.8* 0.23
Population type
Inpatient 11 7.56 (6.52–8.77) 95.4 (94.0–96.3) <0.001
Inpatient and
community
1 6.05 (5.14–7.12) – –
Community 0 – –
Mid-point of study
1950s 1 2.93 (1.52–5.13) – –
1960s 0 – – –
1970s 3 5.46 (3.03–9.85) 84.3 (15.7–93.0) 0.002
1980s 3 8.75 (6.39–11.97) 97.3 (95.4–982) <0.001
1990s 2 6.93 (3.60–13.34) 98.9* <0.001
2000s 3 8.26 (6.53–10.44) 94.9 (91.6–96.6) <0.001
SMR, standardised mortality ratio; CI, confidence interval: I2, index of heterogeneity;
Het P, from chi-square test.
*95% CI cannot be calculated due to 1 degree of freedom.
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graphically and temporally. In many of the
included studies, cause of death was ascertained
from death certiﬁcates and therefore may be sub-
ject to potential misclassiﬁcation bias. Having a
mental health diagnosis has been shown to increase
the risk of a coroners verdict of suicide rather than
accidental or undetermined death (49) but may
also reduce diagnosis of terminal illness leading to
miscoding of physical cause of death (43).
This meta-analysis highlights diﬀerential mortal-
ity in patients with BPAD and the general popula-
tion. Similarly to schizophrenia, patients with
BPAD have over twice the all-cause mortality (50).
Mortality from all physical conditions and unnatu-
ral causes is elevated. Variation in all-cause mor-
tality is considerable across time and place. There
is no evidence that all-cause mortality for patients
with BPAD has improved over time relative to the
general population.
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